-
Mashup Score: 0
Join us for an exciting discussion where expert oncologists in the field of colorectal cancer will deliberate on nuances related to sequencing oral tyrosine kinase inhibitor (TKI) therapies in a manner that considers the patient’s status, strategically allows for an increased time on therapy, and optimizes the mechanism of action of agents to the patient’s previous therapy response patterns. Faculty Marc Peeters, MD, PhD Kanwal P. S. Raghav, MBBS, MD This event is supported by an independent educational grant from Bayer
Source: www.linkedin.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Join us for an exciting discussion where expert oncologists in the field of colorectal cancer will deliberate on nuances related to sequencing oral tyrosine kinase inhibitor (TKI) therapies in a manner that considers the patient’s status, strategically allows for an increased time on therapy, and optimizes the mechanism of action of agents to the patient’s previous therapy response patterns. Faculty Marc Peeters, MD, PhD Kanwal P. S. Raghav, MBBS, MD This event is supported by an independent educational grant from Bayer
Source: www.linkedin.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Join us for an exciting discussion where expert oncologists in the field of colorectal cancer will deliberate on nuances related to sequencing oral tyrosine kinase inhibitor (TKI) therapies in a manner that considers the patient’s status, strategically allows for an increased time on therapy, and optimizes the mechanism of action of agents to the patient’s previous therapy response patterns. Faculty Marc Peeters, MD, PhD Kanwal P. S. Raghav, MBBS, MD This event is supported by an independent educational grant from Bayer
Source: www.linkedin.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Home - 15 day(s) ago
Supported by an independent educational grant from Servier. Join us for an interactive a nd engaging symposium that takes a deep dive into the latest clinical evidence for novel therapies targeting IDH -mutant gliomas and how this can be translated into clinical practice, including expert perspectives on providing individualized, comprehensive care that maximizes long-term outcomes for your patients. Chief, Division of Neuro-Oncology Boston, Massachusetts, United States Miami, Florida, United
Source: events.medscapelive.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Advancements in Breast Cancer Treatment | PBCC 2024 - 16 day(s) ago
Register now and explore groundbreaking advancements in breast cancer treatment at PBCC 2024. Stay informed with the latest innovations shaping the future of breast cancer care and research.
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Home - 17 day(s) ago
Register Now Thursday, May 23, 2024 Time: 11:30 – 12:15 pm ET / 5:30 – 6:15 pm CET CME | CNE | CPE Virtual The therapeutic landscape for treating relapsed/refractory chronic lymphocytic leukemia (R/R CLL) is rapidly evolving, with numerous trials and approvals leading to the availability of multiple treatment options. Though this range of therapies enables the individualization of treatment for patients, it also creates a need to establish optimal treatment sequencing. In this live virtual event, experts
Source: events.medscapelive.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Advancements in Breast Cancer Treatment | PBCC 2024 - 17 day(s) ago
Register now and explore groundbreaking advancements in breast cancer treatment at PBCC 2024. Stay informed with the latest innovations shaping the future of breast cancer care and research.
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Advancements in Breast Cancer Treatment | PBCC 2024 - 18 day(s) ago
Register now and explore groundbreaking advancements in breast cancer treatment at PBCC 2024. Stay informed with the latest innovations shaping the future of breast cancer care and research.
Categories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Home - 19 day(s) ago
Friday, May 3, 2024 | 1:30 pm – 2:30 pm CT Supported by an independent educational grant from Servier. Three pioneers in awake brain surgery, in collaboration with a person living with diffuse low-grade glioma (LGG), will take the audience on a 60-minute journey, from first consultation to the theatre, and beyond. After an update on current and emerging strategies for the management of lower-grade gliomas, key insights on how to optimize tumor resection while preserving patients’ neurological function
Source: events.medscapelive.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Home - 22 day(s) ago
Sunday, June 2, 2024 | 6:45 pm – 8:15 pm CT Supported by an independent educational grant from Takeda Pharmaceuticals, Inc. Join us in Chicago for a timely and important discussion on refractory metastatic colorectal cancer (mCRC). In this 90-minute symposium, a panel of experts in refractory mCRC will guide learners through a number of patient cases to build a strong foundation of information for using new and emerging therapies effectively within their clinical practice and enhance their patient
Source: events.medscapelive.orgCategories: General Medicine News, Onc News and JournalsTweet
Tune in LIVE next week on @Medscape with Marc Peeters and kanwal_raghav as they dive deep into optimizing oral TKI therapies for #colorectalcancer. Discover how sequencing can enhance patient outcomes and therapy effectiveness. Click ➡️ to be notified https://t.co/vCLByVao36 https://t.co/VB62zEEkwa